Sipavibart reduced symptomatic COVID-19 by 34.9% compared to standard treatment, but efficacy was only observed against non–Phe456Leu-containing variants, according to new phase 3 trial data.
New research reveals 25% tariffs on Canadian pharmaceuticals would impact critical medications, strain supply chains, and potentially increase costs—with 28 drugs having no alternative suppliers.
Conexiant
Daily News
Stay up to date with the latest clinical headlines and other information tailored to your specialty.
Thank you for signing up for the Daily News alerts. You will begin receiving them shortly.
Researchers found that awake prone positioning was associated with improved survival without intubation and reduced mortality in patients with COVID-19 and acute hypoxemic respiratory failure.
In a new study on the long-term health risks post–COVID-19 hospitalization, researchers reported an "increased risk of death or hospitalization for various organ disorders up to 30 months after discharge."
Americans report record-low mental and physical health assessments in Gallup survey, with young women experiencing steepest mental health decline since the COVID-19 pandemic began despite end of public health emergency.